IgA NephropathySymptoms, Doctors, Treatments, Advances & More
IgA Nephropathy Overview
Learn About IgA Nephropathy
- IgA nephropathy
- Berger disease
- Berger's disease
- Glomerulonephritis, IGA
- IGAN
- Nephritis, IGA type
Georgia Nephrology
James Tumlin is a Nephrologist practicing medicine in Lawrenceville, Georgia. Dr. Tumlin is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses IgA Nephropathy, Lupus Nephritis, Glomerulonephritis, Focal Segmental Glomerulosclerosis, and Kidney Transplant. Dr. Tumlin is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine - Nephrology. Dr. Tumlin is currently accepting new patients.
CUIMC/Russ Berrie Medical Science Pavilion
"Dr. Ali Gharavi is a kidney specialist with expertise in human genetics. He is the Harold Ames Hatch (II) Professor of Medicine and currently serves as Chair of the Department of Medicine at Columbia University Vagelos College of Physicians and Surgeons, and Physician-in-Chief, NewYork-Presbyterian Hospital/Columbia. He previously served as the Chief of the Division of Nephrology at NewYork-Presbyterian/Columbia University Irving Medical Center.The principal investigator on multiple research projects funded by the National Institutes of Health (NIH), Dr. Gharavi has specific interests in the genetics of kidney diseases, including IgA nephropathy and congenital abnormalities of the kidney and urinary tract. His research has identified genes and risk loci for many kidney diseases and has demonstrated the utility of sequencing for the diagnosis and management of patients with kidney disorders.""Owing to the recent progress in genomic technologies, we now have the opportunity to make a precise genetic diagnosis for many patients and individualize care based on the specific molecular mechanism of disease. My objective is to therefore bring personalized genomic medicine from the laboratory into patient care,"" says Dr. Gharavi. As Department Chair, he aims to enhance access to genomic medicine for patients and reduce disparities for underserved populations.After receiving his medical degree from George Washington University, Dr. Gharavi completed his Internal medicine residency at Mount Sinai Medical Center and fellowships in hypertension and nephrology, also at Mount Sinai. He then completed a postdoctoral fellowship in human genetics at Yale University School of Medicine. He previously held academic appointments at Yale University School of Medicine and Mount Sinai School of Medicine and hospital appointments at Mount Sinai Hospital. Dr. Gharavi is the author of over 200 peer-reviewed publications and has led national and International committees related to genetic testing and research for kidney disorders. He was a recipient of the Judson Daland Prize for Outstanding Clinical Investigation from the American Philosophical Society, the National Kidney Foundation Clinical Scientist Award, and Homer Smith Award from the American Society of Nephrology. He was elected to the American Society of Clinical Investigation and the American Association of Physicians.". Dr. Gharavi is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses IgA Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, and Kidney Transplant. Dr. Gharavi is board certified in Nephrology.
Stanford Hospital And Clinics
Richard Lafayette is a Nephrologist practicing medicine in Stanford, California. Dr. Lafayette is rated as an Elite provider by MediFind in the treatment of IgA Nephropathy. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses IgA Nephropathy, Glomerulonephritis, Focal Segmental Glomerulosclerosis, Chronic Kidney Disease, and Kidney Transplant.
Summary: The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Summary: In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much d...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

